Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipagladenant in early Parkinson's disease
NCT02939391Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Sep 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sipagladenant in Parkinson's disease (PD) (3 arms), sponsored by Kyowa Kirin. Primary endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
sipagladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02939391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939391.